Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...